Project Grant R01AI183879
Award Date
8/16/24
Completion Date
7/31/29
Dollars Obligated
$769K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is supporting research to investigate the role of T cells in promoting post-acute memory deficits after COVID-19 infection in mice. The $107,995 award to The Washington University, which runs from July 2025 to June 2027, will fund a study to determine how pathogenic CD4+ T cells are recruited to the central nervous...
This $583,047 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how Rift Valley Fever Virus (RVFV) disseminates from the site of infection in the skin to the central nervous system (CNS). The project aims to establish the routes and mechanisms by which RVFV invades the CNS following peripheral exposure, using novel rodent CNS infection models...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $413,542 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Charlotte. The 2-year grant, effective August 1, 2025, will fund research to develop a novel nanoparticle-based therapeutic approach for targeting glial cells in the central nervous system. The goal is to limit both intracellular bacterial burden and glia-driven neuroinflammation during...
This $477,226 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to discover novel antiviral systems in microbial eukaryotes. The research will focus on understanding how the amoeba genus Acanthamoeba defends against giant viruses called Megavirales, and then expand that knowledge to other microbial eukaryotes. The project will leverage cutting-edge AI techniques and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $790,000.00 in funding to the Regents of the University of Minnesota to conduct research on the immune response to West Nile virus (WNV) and the factors that influence the development of neuroinvasive disease. The goal is to gain a molecular understanding of WNV neuroinvasion, central nervous system immunity, and the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $254,250 to New York University (NYU) from July 1, 2025 to June 30, 2027. The funding supports research to understand how pathogenic alphaviruses, such as chikungunya virus, infect and spread through human microvascular endothelial cells. The research aims to identify viral and host factors that restrict alphavirus...
This Project Grant award, valued at $430,170.00 and provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 Allergy and Infectious Diseases Research, supports research to identify genetic determinants of neurotropism in Enterovirus D68 (EV-D68). The overarching goal is to utilize a human spinal cord organoid (HSCO) model to determine viral genetic factors that enable EV-D68 to target the central nervous system and cause acute flaccid myelitis, a...
This Project Grant award of $186,451.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to characterize the molecular mechanism of CD4+ T cell migration to the brain during HIV/AIDS-associated cryptococcal immune reconstitution inflammatory syndrome (IRIS). The primary goals are to determine whether TNF-α signaling and CD11a expression mediate CD4+ T cell migration to the brain in...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 2-year, $544,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the Texas Biomedical Research Institute to characterize a novel mouse model for studying the neurological impacts of Chikungunya virus infection. The research aims to determine the mechanisms by which Chikungunya virus infects the brain and evaluate whether the mouse model develops the...
The University of Colorado-Denver received a $782,871 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The grant supports research to define mechanisms by which arthritogenic alphaviruses, such as chikungunya and Ross River viruses, evade CD8+ T cell-mediated clearance. The research aims to investigate how type I interferon signaling restricts myeloid cell infection...